PharmaPendium® and Embase™:
Improving drug safety decisions with more comprehensive searches
PP-EM can impact critical drug safety decisions with needed evidence

Help improve drug safety decisions for:

- Risk management and mitigation
- Post-market surveillance
- Preclinical and clinical study designs
New Functionality in PharmaPendium links to Embase

- A new “Search in Embase” button appears on the PharmaPendium “Quick Search” results page

- Duplicates PharmaPendium search query directly into Embase
- Saves time and provides more consistent search results between the two products

Look for this PharmaPendium by March 3, 2015, or sooner
Example: Use PP-EM to support experimental findings on cardiac safety

Find evidence to support an indication for a new drug candidate that acts on smooth muscle cells and has few cardiovascular adverse effect. The drug is very similar to one on market. The company wants to have more supportive evidence.

- Ezogabine, an antiepileptic drug as adjunctive therapy for partial-onset seizures in patients 18 years and older. Approved in 2011. What data was submitted about Ezogabine effects on smooth muscle cells and the effect on cardiac tissue?

Start in PharmaPendium

Type in search term(s)

Click on document link to view it
Example: Use PP-EM to support experimental findings on cardiac safety

Find evidence to support an indication for a new drug candidate that acts on smooth muscle cells and has few cardiovascular adverse effects. The drug is very similar to one on the market. The company wants to have more supportive evidence.

- Ezogabine, an antiepileptic drug as adjunctive therapy for partial-onset seizures in patients 18 years and older. Approved in 2011. What data was submitted about Ezogabine effects on smooth muscle cells and the effect on cardiac tissue?

Data from a dog and pig study suggest that a slight decrease in blood pressure was not accompanied by the expected reflex tachycardia.
**Example:** Use PP-EM to support experimental findings on cardiac safety

Launch Embase through the “Search in Embase” function to see if any Post-Market study updates have been published as further evidence.
Example: Use PP-EM to support experimental findings on cardiac safety

Launch Embase through the “Search in Embase” function to see if any Post-Market study updates have been published as further evidence.

This article suggests that Ezogabine could be a useful combination treatment for asthma.

Evidence suggest that Ezogabine may play a role in improving impaired periadventitial vasoregulation and associated hypertension.
Example: Use PP-EM to support experimental findings on cardiac safety

Summary of findings

- From PharmaPendium:
  - Ezogabine data indicates “…little effect on heart and its nervous system..”
- From Embase, published information of post-market studies using Ezogabine:
  - Found 2 additional indications beyond that of partial-onset seizure control
  - Both act on smooth muscle cells

- Together, this information can help inform preclinical study designs to further characterize new drug candidates
  - Findings can be leveraged to further strengthen scientific data
  - Regulatory and literature evidence can support preclinical data package
  - Help uncover unanticipated clinical risks
A company is interested in finding post-market published information on Tafluprost, a drug in the same class as one of the company’s drug candidates that is entering clinical trials. This information could offer additional insights into potential testing that may be required during clinical development.

- First, explore post-market requirements for Tafluprost in PharmaPendium to determine if post-market studies were required and, if so, what were the designs?

Example: PP-EM can inform Clinical Study Designs

Type in search term(s)

Post-Market studies for Tafluprost approval
Example: PP-EM can inform Clinical Study Designs

Next, click on the “Search in Embase” link to see the Embase search results. An article that aligns to the requirements for additional post-market studies as stated in the table from PharmaPendium is found.

At the 2 month time point of a 2 year study, Tafluprost provided greater efficacy than the two other drugs.
Example: PP-EM can inform Clinical Study Designs

Summary of findings

• Tafluprost received approval with a commitment by the sponsor to complete several post-market studies
  • Several studies focused on Japanese patient populations
  • This information may be useful during agency reviews (cite, supporting evidence, clinical study designs for patient subgroups) and informing potential clinical trials study designs for specific patient populations
• As the study is over a 2 year period, information on long term use will emerge that could impact:
  • Post-market testing requirements
  • REMS planning to better understand how to mitigate any potential safety risks/concerns
  • Clinical trial designs for specific patient populations
• Data from this required post-market study was only found in Embase
• Critical information from both PharmaPendium and Embase helps support decisions on clinical trial designs
More comprehensive information and resources can impact drug safety decisions

Post-Market
- Help define potential post-market testing requirements
- Improve REMS planning by providing a better understanding of how to mitigate any potential safety risks/concerns
- Improve clinical trial designs for specific patient populations

Risk Management / Mitigation
- Leverage findings to further strengthen scientific data
- Support regulatory reviews with regulatory and literature evidence
- Help uncover unanticipated clinical risks
Thank you